HUTCHMED (China) (HCM) Cash & Equivalents (2014 - 2026)

HUTCHMED (China) (HCM) has reported Cash & Equivalents for 13 consecutive years, with $106.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents fell 3.76% year-over-year to $106.6 million; the TTM figure through Jun 2026 stood at $106.6 million (down 3.76% YoY), while the FY2025 annual figure was $71.3 million, down 33.43% from the prior year.
• Cash & Equivalents retreated to $106.6 million in Q2 2026 per HCM's latest filing, from $175.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $467.5 million in Q2 2022 and bottomed at $113433.7 in Q4 2023.
• Historically, Cash & Equivalents has averaged $164.0 million across 5 years, with a median of $110.7 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 99.86% — and 2024, when it jumped 94712.72%.
• HUTCHMED (China)'s Cash & Equivalents stood at $80.7 million in 2022, then plunged by 99.86% to $113433.7 in 2023, then surged by 94712.72% to $107.5 million in 2024, then soared by 63.46% to $175.8 million in 2025, then slumped by 39.39% to $106.6 million in 2026.
• Business Quant data shows HCM's Cash & Equivalents at $106.6 million in Q2 2026, $175.8 million in Q4 2025, and $110.7 million in Q2 2025.